A phase 1b trial investigated the combination therapy of TLR-9 agonist CMP-001 and pembrolizumab in patients with unresectable or metastatic melanoma with either stable disease after 12 weeks or progressive disease during or after anti-PD-1 therapy. This evidence concerns the gene TLR9 and metastatic melanoma.